诺华个性化免疫疗法Kymriah包括从病人体内抽取 T 细胞、对其进行基因改造以针对性攻击癌细胞、最后将其输回到病人体内的全过程。但单次治疗价格47.5万美元，遭受外界强烈批评。
It's not unusual for critics to challenge top drugmakers for price hikes on old drugs, but Novartis is contending with a different kind of pricing pressure from a Swiss shareholder activist group.
对于批评人士来说，挑战顶级制药企业提高老药品价格并不罕见，但诺华（Novartis）正面临来自瑞士股东维权组织的另一种定价压力。
In this case, it's the company's move into ultra-expensive, one-time treatments that has critics riled. At the Swiss drugmakers' annual meeting Thursday, the investment firm Actares questioned Novartis’ rollout prices on cell and gene therapies and whether they're sustainable for payers.
在这种情况下，这是该公司进入超昂贵的一次性治疗，批评人士愤怒。在瑞士制药公司周四召开的年度会议上，投资公司 Acares 质疑了诺华（Novartis）在细胞和基因治疗方面的推出价格，以及它们是否对纳税人具有可持续性。
The investors say they've been questioning drug prices for years, especially in cancer, but Novartis has taken the issue a step further by deciding to specialize in the new wave of treatments, starting with the cell therapy Kymriah it launched in 2017.Novartis believes six- and seven- digit prices for such drugs are “justified,” Actares said in a statement, according to a translation.
投资者表示，他们多年来一直在质疑药品价格，尤其是在癌症领域，但诺华（Novartis）已采取进一步措施，决定专注于新一轮治疗，从2017年推出的细胞疗法 Kymriah 开始。诺华（Novartis）公司在一份声明中说，这种药物的六位数和七位数的价格是“合理的”。
Novartis rolled out Kymriah at a list price of $475,000, and the company has said its forthcoming spinal muscular atrophy gene therapy, Zolgensma, would be cost-effective at a price of $4 million to $5 million. The company hasn't announced a launch price for Zolgensma.
诺华（Novartis）以47.5万美元的标价推出了 Kymriah ，该公司表示，其即将推出的脊柱肌肉萎缩基因疗法 Zolgensma 将具有成本效益，价格在400万至500万美元之间。该公司尚未宣布 Zolgensma 的上市价格。
Novartis CEO Vas Narasimhan said at Thursday’s meeting that the company prices drugs based on value and seeks a fair return for more R&D, according to Reuters.
据路透社( Reuters )报道，诺华( Novartis )首席执行长纳拉希姆( Vas Narasimhan )在周四的会议上表示，该公司根据价值为药品定价，并寻求更多研发的公平回报。
“With respect to pricing in cell and gene therapies, I think what’s often lost in the discussion is the remarkable impact of these medicines,” Narasimhan said at the meeting, as quoted by the news service. “These are true breakthroughs that come from a single infusion of a medicine that don’t require lifelong therapy.”
“关于细胞和基因疗法的定价，我认为讨论中经常失去的是这些药物的显著影响，” Narasimhan 在会议上说，这是由新闻服务引用的。“这些都是真正的突破，来自于一种不需要终身治疗的药物的单一输注。”这是一个很好的例子
閱讀更多 匯眾醫療 的文章
